Does Negative Inotropes Interact with Mavacamten?
CDI records a major classification for Negative Inotropes and Mavacamten. The stored summary is: Close medical supervision and LVEF monitoring recommended if a negative inotrope is initiated or dose increased. Avoid certain combinations of negative inotropes. The mechanism involves additive negative inotropic effects may increase heart failure risk. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Mavacamten Class
- Cardiac Myosin Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Additive negative inotropic effects may increase heart failure risk
What To Tell Your Doctor or Pharmacist
If you are taking Negative Inotropes and your doctor is considering prescribing Mavacamten (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider